CIK 0001326110 · Large accelerated filer
ImmunityBio, Inc.
Sign in to watch- Ticker
- IBRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 431979754
- Phone
- (844) 696-5235
- Business address
- 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121
- Former names
- NantKwest, Inc., Conkwest, Inc., ZelleRx Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,119,848
- in 2 filings, $1.1M under 10b5-1 plans
Net −$1,119,848. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-22 | Simon Barry J. Director | Shares withheld for taxes | −5,453 | $3.42 | $19K | 3,243,571 |
| 2025-02-22 | Simon Barry J. Director | Option exercise · Restricted Stock Units | −15,243 | 30,488 | ||
| 2025-02-10 | SOON-SHIONG PATRICK See remarks | Grant or award · Restricted Stock Units | +822,368 | 822,368 | ||
| 2025-02-10 | SOON-SHIONG PATRICK See remarks | Grant or award · Stock Option (right to buy) | +2,812,500 | 2,812,500 | ||
| 2025-02-10 | LAUER REGAN J Chief Accounting Officer | Grant or award · Restricted Stock Units | +16,447 | 16,447 | ||
| 2025-02-10 | LAUER REGAN J Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +56,250 | 56,250 | ||
| 2025-02-10 | Sachs David C. Chief Financial Officer | Grant or award · Restricted Stock Units | +246,710 | 246,710 | ||
| 2025-02-10 | Sachs David C. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +843,750 | 843,750 | ||
| 2025-02-10 | Adcock Richard CEO & President | Grant or award · Restricted Stock Units | +822,368 | 822,368 | ||
| 2025-02-10 | Adcock Richard CEO & President | Grant or award · Stock Option (right to buy) | +2,812,500 | 2,812,500 | ||
| 2025-01-22 | Simon Barry J. Director | Option exercise | +110,020 | $2.00 | $220K | 3,233,781 |
| 2025-01-22 | Simon Barry J. Director | Option exercise · Stock Option (right to buy) | −110,020 | 0 | ||
| 2024-12-31 | Adcock Richard CEO & President | Option exercise | +34,483 | 277,621 | ||
| 2024-12-31 | Adcock Richard CEO & President | Shares withheld for taxes | −17,475 | $2.56 | $45K | 260,146 |
| 2024-12-31 | Adcock Richard CEO & President | Option exercise · Restricted Stock Units | −34,483 | 86,214 | ||
| 2024-12-31 | Sachs David C. Chief Financial Officer | Option exercise | +30,397 | 216,235 | ||
| 2024-12-31 | Sachs David C. Chief Financial Officer | Shares withheld for taxes | −15,405 | $2.56 | $39K | 200,830 |
| 2024-12-31 | Sachs David C. Chief Financial Officer | Option exercise · Restricted Stock Units | −30,397 | 75,999 | ||
| 2024-12-15 | LAUER REGAN J Chief Accounting Officer | Option exercise | +21,031 | 115,365 | ||
| 2024-12-15 | LAUER REGAN J Chief Accounting Officer | Shares withheld for taxes | −7,503 | $2.87 | $22K | 107,862 |
Page 6 of 12 · 226 trades